Karen L Syrjala1, Steven K Sutton2, Heather S L Jim3, Jennifer M Knight4, William A Wood5, Stephanie J Lee1, Paul B Jacobsen3, Muneer H Abidi6, Jean C Yi7. 1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 2. Biostatistics Department, Moffitt Cancer Center, Tampa, Florida. 3. Health Outcomes and Behavior Department, Moffitt Cancer Center, Tampa, Florida. 4. Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 5. Division of Hematology/Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 6. Division of Hematology/Oncology, Spectrum Health Cancer Center, Michigan State University, Detroit, Michigan. 7. Biobehavioral Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study ShortForm-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS:Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were .94, .95, and .95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α = .77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416-1423.
RCT Entities:
BACKGROUND: Routine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients. METHODS: As a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT. RESULTS: Across 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were .94, .95, and .95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α = .77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity. CONCLUSIONS: The CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416-1423.
Authors: William F Pirl; Jesse R Fann; Joseph A Greer; Ilana Braun; Teresa Deshields; Caryl Fulcher; Elizabeth Harvey; Jimmie Holland; Vicki Kennedy; Mark Lazenby; Lynne Wagner; Meghan Underhill; Deborah K Walker; James Zabora; Bradley Zebrack; Wayne A Bardwell Journal: Cancer Date: 2014-05-02 Impact factor: 6.860
Authors: A M J Braamse; B van Meijel; O Visser; P C Huijgens; A T F Beekman; J Dekker Journal: Bone Marrow Transplant Date: 2013-10-07 Impact factor: 5.483
Authors: Can-Lan Sun; John H Kersey; Liton Francisco; Saro H Armenian; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia Journal: Biol Blood Marrow Transplant Date: 2013-04-10 Impact factor: 5.742
Authors: Eric J Chow; Lynnette Anderson; K Scott Baker; Smita Bhatia; Gregory M T Guilcher; Jennifer T Huang; Wendy Pelletier; Joanna L Perkins; Linda S Rivard; Tal Schechter; Ami J Shah; Karla D Wilson; Kenneth Wong; Satkiran S Grewal; Saro H Armenian; Lillian R Meacham; Daniel A Mulrooney; Sharon M Castellino Journal: Biol Blood Marrow Transplant Date: 2016-01-21 Impact factor: 5.742
Authors: Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer Journal: J Clin Oncol Date: 2010-01-11 Impact factor: 44.544
Authors: Karen L Syrjala; Shelby L Langer; Janet R Abrams; Barry Storer; Jean E Sanders; Mary E D Flowers; Paul J Martin Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: Heather S L Jim; Steven K Sutton; Paul B Jacobsen; Paul J Martin; Mary E Flowers; Stephanie J Lee Journal: Cancer Date: 2016-01-27 Impact factor: 6.860
Authors: Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Joan M Romano; Marie-Laure Crouch; Allison S Fiscalini; Mark T Hegel; Mary E D Flowers; Paul J Martin; Wendy M Leisenring Journal: J Cancer Surviv Date: 2018-05-05 Impact factor: 4.442
Authors: Claire J Han; Biljana Gigic; Martin Schneider; Yakup Kulu; Anita R Peoples; Jennifer Ose; Torsten Kölsch; Paul B Jacobsen; Graham A Colditz; Jane C Figueiredo; William M Grady; Christopher I Li; David Shibata; Erin M Siegel; Adetunji T Toriola; Alexis B Ulrich; Karen L Syrjala; Cornelia M Ulrich Journal: J Cancer Surviv Date: 2020-03-12 Impact factor: 4.442
Authors: Jessica Liang; Stephanie J Lee; Barry E Storer; Bronwen E Shaw; Eric J Chow; Mary E Flowers; Elizabeth F Krakow; Merav Bar; Karen L Syrjala; Rachel B Salit; Chareeni E Kurukulasuriya; Heather S L Jim Journal: Biol Blood Marrow Transplant Date: 2018-08-09 Impact factor: 5.742
Authors: Michelle B Riba; Kristine A Donovan; Barbara Andersen; IIana Braun; William S Breitbart; Benjamin W Brewer; Luke O Buchmann; Matthew M Clark; Molly Collins; Cheyenne Corbett; Stewart Fleishman; Sofia Garcia; Donna B Greenberg; Rev George F Handzo; Laura Hoofring; Chao-Hui Huang; Robin Lally; Sara Martin; Lisa McGuffey; William Mitchell; Laura J Morrison; Megan Pailler; Oxana Palesh; Francine Parnes; Janice P Pazar; Laurel Ralston; Jaroslava Salman; Moreen M Shannon-Dudley; Alan D Valentine; Nicole R McMillian; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Mohamad S Alabdaljabar; Ibrahim N Muhsen; Jennifer M Knight; Karen L Syrjala; Shahrukh K Hashmi Journal: Blood Rev Date: 2020-12-01 Impact factor: 8.250
Authors: Casey A Walsh; Jean C Yi; Abby R Rosenberg; Marie-Laure V Crouch; Wendy M Leisenring; Karen L Syrjala Journal: Psychooncology Date: 2020-08-13 Impact factor: 3.894
Authors: Salene M W Jones; Jean C Yi; Heather S L Jim; Alison W Loren; Navneet S Majhail; Joseph Uberti; Victoria Whalen; Wendy M Leisenring; Mary E D Flowers; Stephanie J Lee; Karen L Syrjala Journal: Support Care Cancer Date: 2020-01-08 Impact factor: 3.603
Authors: Karen L Syrjala; Marie-Laure Crouch; Wendy M Leisenring; Mary E D Flowers; Samantha B Artherholt; Allison Stover Fiscalini; Eleni Romano; Joan M Romano; Paul J Martin; Jean C Yi Journal: Biol Blood Marrow Transplant Date: 2018-05-09 Impact factor: 5.742
Authors: Karen L Syrjala; Hélène Schoemans; Jean C Yi; Shelby L Langer; Ahona Mukherjee; Lynn Onstad; Stephanie J Lee Journal: Transplant Cell Ther Date: 2020-09-29